Retatrutide: Why the Triple Agonist is Called the "Heavy Artillery" of Weight Loss

Imagine you've been trying to open a door for years by pushing with one shoulder. Then someone suggested pushing with both hands. And now there's a key that simply turns in the lock.

This is how we can describe the evolution of weight correction products: from one receptor to two, and now — to three. Retatrutide became the first triple agonist activating GLP-1, GIP, and glucagon receptors simultaneously. And Phase 2 study results impressed even skeptics.

But here's what's important to understand before you message DOZA: this product isn't for everyone. Not because it's bad. But because it's too powerful for starting.

What is Retatrutide and why is everyone talking about it?

Retatrutide is a synthetic peptide developed by Eli Lilly. The molecule is created based on experience with tirzepatide (the active substance in Mounjaro), but with the addition of a third mechanism — activation of glucagon receptors.

To understand the scale, let's compare generations:

• Ozempic — semaglutide — activates 1 receptor (GLP-1)
• Mounjaro — tirzepatide — activates 2 receptors (GLP-1 + GIP)
• Retatrutide — activates 3 receptors (GLP-1 + GIP + glucagon)

Each additional receptor is a new channel of influence on metabolism. And it's precisely the third one, glucagon, that makes Retatrutide unique.

In Ukraine through DOZA, retatrutide is available from three manufacturers: ALLUVI Healthcare, SYNEDICA Laboratories (Germany), and PEN PEPTIDE. This is NOT original Eli Lilly product, which isn't on market yet. These are analogs manufactured with the same formula.

How the triple mechanism works — and why it changes the game?

Each of the three receptors handles its part of metabolism. When they work together, synergy emerges — an effect greater than the sum of parts.

GLP-1 receptor: less appetite

Glucagon-like peptide-1 is a hormone produced in intestine after eating. It sends brain the signal: "Enough, we're full." Retatrutide mimics this hormone, so hunger feeling disappears long before you eat your usual portion.

Additionally, GLP-1 slows gastric emptying. Food stays inside longer, so satiety lasts for hours.

GIP receptor: better insulin function

Glucose-dependent insulinotropic polypeptide handles how body responds to carbohydrates. When GIP is active, pancreas produces exactly as much insulin as needed. No more, no less.

This matters because excess insulin is one factor in weight gain. GIP also improves fat tissue metabolism, helping it efficiently "release" stored energy.

Glucagon receptor: maximum fat burning

And here's where the real magic of triple agonist begins.

Glucagon is hormone opposite to insulin. If insulin says "store," glucagon says "spend." Glucagon receptor activation triggers three processes:

1. Thermogenesis — body produces more heat, spending calories even at rest
2. Lipolysis — fat cells more actively release stored fat for energy use
3. Liver fat reduction — glucagon helps "clear" liver of excess fat

It's precisely the glucagon component that distinguishes Retatrutide from Mounjaro. And it's precisely this component that is likely responsible for the additional percentage of weight loss.

Phase 2 results: minus 24.2% weight in 48 weeks

In July 2023, New England Journal of Medicine published Phase 2 retatrutide study results. Study was conducted by Amos Jastreboff and team under Eli Lilly guidance.

Key study parameters:

• Participants: 338 adults with obesity or overweight
• Duration: 48 weeks
• Doses: from 1 mg to 12 mg weekly
• Control group: placebo

Results by dose

24.2% isn't just a number. For 100 kg person, this means minus 24 kg in a year. Without surgery. Without exhausting diets. One injection per week.

But there's an important "but." This is Phase 2 with 338 participants. For comparison:

• SURMOUNT-1 (Mounjaro) — 2539 participants
• STEP-1 (Ozempic) — 1961 participants

Phase 3 TRIUMPH study with thousands of participants is still ongoing. Results may differ.

Retatrutide vs Mounjaro vs Ozempic: the big comparison

This is the most frequent question: which product to choose? Let's break it down in detail.

What do the numbers tell us?

At first glance, Retatrutide is the clear winner. But this is comparing apples to oranges:

1. Different study phases. Comparing Phase 2 (338 participants) with Phase 3 (2,539 participants) is methodologically incorrect. Phase 3 has stricter criteria and often shows more modest results.
2. Different populations. Study participants differed by age, weight, comorbidities. Direct comparison impossible without randomized head-to-head study.
3. Different experience. Ozempic and Mounjaro have been used by millions of people for years. Retatrutide is a newcomer with limited experience.

Read more about the difference between Mounjaro and Ozempic in a separate article.

Retatrutide dosing: week-by-week schedule

Proper dosing is key to balancing efficacy and comfort. Too rapid dose increase leads to side effects. Too slow — to disappointment.

Standard titration schedule (ALLUVI / SYNEDICA)

Some DOZA clients stay on 7.5 mg if effect is sufficient and comfort is maximum. Others progress to 10 mg and higher. Everything is individual.

Administration — subcutaneous injection once weekly. Areas: abdomen, thigh, or shoulder. Time doesn't matter, main thing is stable 7-day interval between injections.

Retatrutide side effects: what to expect?

Every active product has side effects. Retatrutide is no exception. But the safety profile in Phase 2 proved to be acceptable and similar to Mounjaro.

Most common side effects (Phase 2, N=338)

Important observations:

• Dose-dependency. Higher dose, more frequent side effects. That's why slow titration isn't whim, but necessity.
• Transience. In most participants, symptoms disappeared within first 4-6 weeks as body adapted.
• No serious events. Phase 2 study recorded no serious adverse events related to retatrutide.

Safety profile comparison

Retatrutide side effects are similar to Mounjaro. This is logical since both products share mechanisms — GLP-1 and GIP. Glucagon component didn't add new side effect categories in Phase 2.

From our DOZA experience: clients who previously tolerated Mounjaro well usually tolerate Retatrutide well. Those who had pronounced nausea on Mounjaro can expect similar reaction.

When will Retatrutide appear officially on market?

This question concerns many. If Phase 2 showed such results, when can we buy "real" Retatrutide from Eli Lilly?

Eli Lilly roadmap

Phase 3 TRIUMPH studies:

• TRIUMPH-1 — efficacy in obesity
• TRIUMPH-2 — efficacy in type 2 diabetes
• TRIUMPH-3 — long-term safety

Expected timeline:

• Phase 3 results: 2026-2027
• FDA submission: approximately 2027-2028
• Possible approval: 2028-2029

So until official original product launch — minimum 2-3 years.

How to try Retatrutide in Ukraine?

While Eli Lilly conducts Phase 3, DOZA offers retatrutide from three alternative manufacturers. Each produces product with same formula as original molecule.

Manufacturers in DOZA catalog

ALLUVI Healthcare

• Format: 40 mg pen (4 doses of 10 mg each)
• Price: 18,000 UAH
• Origin: international manufacturer

SYNEDICA Laboratories

• Format: 40 mg pen
• Price: 18,000 UAH
• Origin: Made in Germany
• Verification: synedica.io/verify

PEN PEPTIDE (dtspharmacy.com)

• Formats: 6, 12, 20, 40 mg pens
• Dosing flexibility
• Suitable for different therapy stages

Individual doses

For those who want to start with a minimal dose or select the exact amount, DOZA offers individual doses from 1.5 mg. Price starts from 1,500 UAH.

Each client receives specialist support throughout the course. This is included in price.

Why is the price justified? First, retatrutide is newest and most powerful product in its class. Second, each pen comes with specialist consultation. Third, you get verified product from trusted manufacturers, not unknown powder from internet.

Why NOT to start with Retatrutide: DOZA's step approach

And now — the most important part of this article. The one distinguishing honest consultation from sales.

Retatrutide is "heavy artillery." And like any heavy artillery, it has its place. But not on the front line.

Step approach logic

Imagine you're playing chess and have three pieces: knight, bishop, and queen. Would you start the game with queen? No. Because if you spend your most powerful piece at start, you'll have nothing left for endgame.

Same with weight correction products:

Why this matters?

1. Reserve for plateau. Everyone losing weight eventually meets plateau — moment when weight stops decreasing. If you're already at maximum, nowhere to escalate.
2. Receptor adaptation. Body gets used to stimulation. Starting with triple agonist leaves no room for effect enhancement.
3. Economics. Mounjaro is cheaper than Retatrutide. If Mounjaro is sufficient — why pay more?
4. Safety. More mechanisms involved, more complex body reaction. Better understand your tolerance on simpler product.

When to start with Retatrutide anyway?

There are exceptions:

• You've completed Mounjaro course and reached plateau
• You have significant excess weight (BMI > 40) and need rapid results for medical reasons
• You've tried both Ozempic and Mounjaro, both gave insufficient effect

In such cases, Retatrutide may be justified choice. But decision made individually with DOZA specialist.

What do those who tried it say?

At the time of writing this article, Retatrutide does not yet have mass application experience like Mounjaro or Ozempic. But the first reviews from DOZA clients are encouraging.

Marina, 42, Kyiv: "I was on Mounjaro 10 mg for six months. Lost 18 kg, but last 2 months — plateau. Switched to Retatrutide 7.5 mg. First month — another minus 4 kg. Appetite just disappeared. Don't finish even half portion."

Andriy, 38, Odesa: "Started with Ozempic, then Mounjaro, now Retatrutide. Each step gave additional effect. On Retatrutide — least thoughts about food. Just forget to eat."

More reviews can be found on the results page.

Available Retatrutide doses directly through DOZA: Retatrutide 6 mg — initial phase; Retatrutide 10 mg — therapeutic medium; Retatrutide 12 mg — dose from Phase 2 (-24.2% weight); Retatrutide 20 mg and Retatrutide 40 mg — high-dose options for experienced users. Pen Peptide, thermal box 2–8 °C, 1–2 days across Ukraine. Before starting — mandatory DOZA consultation for starting dose selection.

Conclusion: power requires wisdom

Retatrutide is indeed the most powerful weight correction product among all existing today. Triple mechanism of action, 24.2% weight loss in Phase 2, safety profile similar to Mounjaro — all impressive.

But power isn't synonym of correctness.

If you have never tried GLP-1 agonists, start with Mounjaro. If Mounjaro gave results — continue. And only if you have reached a plateau and the goal is still far — then Retatrutide will become your next step.

DOZA specialists will help determine which product suits you. Consultation is free and without obligations.

Or message directly on Telegram: @Doza_sofia_bot

Because the best product is the one selected for you. Not the most powerful on paper.

Where to order Mounjaro in Ukraine

Ready to start a course? Buy Mounjaro in Ukraine is available in DOZA catalog — all 6 doses (2.5, 5, 7.5, 10, 12.5, 15 mg) with official thermal delivery within 24 hours and 24/7 specialist support. Current Mounjaro prices 2026 — from 1,000 ₴ for a test dose or 8,000 ₴/month for a full program with monitoring.

Where to order DOZA products

DOZA supplies all products mentioned in article with official cold chain and 24/7 specialist support. Choose what you need:

• Buy Ozempic in Ukraine — original semaglutide from Novo Nordisk with thermal delivery. Current Ozempic prices 2026 — from 1,600 ₴ for a starting dose.

Ready to try? Retatrutide in DOZA catalog — detailed product page with dosing description, thermal delivery 2–8°C and free specialist consultation.

Where to buy

DOZA supplies the products mentioned in this article with an official cold chain and 24/7 specialist support:

• Buy Retatrutide in Ukraine — next-generation triple agonist (GLP-1 + GIP + glucagon), ALLUVI and SYNEDICA pens with cold-chain delivery.